Michael Hemann
Tumor biology, Tumor microenvironment


PhD, Johns Hopkins University, 2001

My laboratory is focused on understanding how nests of tumor cells, termed Minimal Residual Disease, or MRD, can survive for a sustained period of time in a dormant state after chemotherapy. Our work has led to the identification of specific tissue microenvironments that promote the survival of tumor cells after treatment. By understanding how these anatomical sites protect cancer cells, we have been able to develop strategies to resensitize tumors to front-line chemotherapy. Importantly, metastatic disease shows many of the characteristics of MRD. Hence, our work should lead to novel strategies to sensitize drug-resistant metastatic cells to existing therapies.

Ludwig Center at MIT
77 Massachusetts Avenue, 76-158
Cambridge, Massachusetts, U.S. 02139

T 617 258 5159
F 617 258 5213


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?